Allogene Therapeutics, Inc. insider trading
Every open-market purchase and sale by Allogene Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Allogene Therapeutics, Inc.’s insiders pay?
From May 15, 2019 to October 23, 2026, 19 insiders reported 4 open-market purchases and 50 sales not made under a pre-set plan in Allogene Therapeutics, Inc. Twelve months after each purchase was reported, the shares were −47.5% against the S&P 500 on average (median −32.4%), over 3 purchases with a full year of prices; 0% beat the index. After sales, the shares moved −48.2% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on June 5, 2020 into $3,713 by November 2, 2026, −14.4% a year. It held shares 31% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $13,962 (+5.4% a year), and held throughout $25,901 (+16.1%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Chang David D | President and CEO | 0 | — | — | 7 | −36.3% (3) | March 18, 2026 |
| Amado Rafael | EVP of R&D and CMO | 0 | — | — | 5 | −52.8% (5) | May 19, 2022 |
| Witte Owen N. | Director | 0 | — | — | 5 | −55.1% (5) | August 15, 2022 |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer | 0 | — | — | 4 | — | March 18, 2026 |
| Roberts Zachary | EVP of R&D | 0 | — | — | 4 | — | February 4, 2026 |
| Belldegrun Arie | Director | 3 | −55.0% (2) | 0% | 0 | — | May 20, 2024 |
| Coulter James G | Director | 0 | — | — | 3 | −37.6% (3) | June 25, 2020 |
| Douglas Earl Martin | SVP, General Counsel | 0 | — | — | 3 | — | August 25, 2026 |
| Moore Alison | Chief Technical Officer | 0 | — | — | 3 | −36.3% (3) | March 17, 2022 |
| Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 0 | — | — | 3 | — | October 23, 2026 |
| Schmidt Eric Thomas | Chief Financial Officer | 0 | — | — | 3 | −36.3% (3) | March 17, 2022 |
| Humer Franz B | Director | 0 | — | — | 2 | — | December 9, 2024 |
| Tpg Group Holdings (sbs) Advisors, Inc. | Director | 0 | — | — | 2 | −76.6% (2) | June 30, 2020 |
| Yoshiyama Annie | SVP, Finance | 0 | — | — | 2 | — | April 23, 2026 |
| Bhavnagri Veer | General Counsel | 0 | — | — | 1 | −36.3% (1) | March 17, 2022 |
| Bonderman David | Director | 0 | — | — | 1 | −83.6% (1) | June 22, 2020 |
| Kazam Joshua A | Director | 1 | −32.4% (1) | 0% | 0 | — | January 14, 2022 |
| Mayo Stephen | Director | 0 | — | — | 1 | — | August 9, 2023 |
| Moore Timothy L. | Chief Technical Officer | 0 | — | — | 1 | — | February 5, 2025 |
When several insiders traded Allogene Therapeutics, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Allogene Therapeutics, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged +17.9% against the index. After 3 selling crowds, +21.8%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| March 31, 2022 | 5 selling | +41.6% | +38.8% | −36.7% |
| January 31, 2022 | 2 buying | −12.8% | +17.9% | −23.2% |
| March 31, 2021 | 4 selling | −34.5% | −37.4% | −90.8% |
| March 31, 2020 | 3 selling | +100.1% | +64.0% | +25.4% |